Joseph P. McGuirk - Concepedia

Author

Joseph P. McGuirk

University of Kansas Medical Center ORCID

Also Known As

J McGuirk, J P McGuirk, J. McGuirk, J. Mcguirk, J. P. McGuirk, J. P. Mcguirk, J.P. McGuirk, J.P. Mcguirk, JOSEPH MCGUIRK, Joseph McGuirk

819

Publications

17.6K

Citations

H-Index

128

Concepts

All Affiliations

University of Kansas Medical Center The University of Texas MD Anderson Cancer Center Moffitt Cancer Center The University of Kansas Cancer Center Cleveland Clinic

About

Joseph P. McGuirk is an author at University of Kansas Medical Center specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	64	3.9K
2	Health Sciences	17	22	1.3K
3	Public Health	3	3	208
4	Natural Sciences	1	1	14
5	Allergy	1	1	11

Joseph P. McGuirk

166

Publications

15.3K

Citations

H-Index

Page 1

	Year	Citations
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma Stephen J. Schuster, Michael Bishop, Constantine S. Tam, New England Journal of Medicine	2018	3.9K
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma Frederick L. Locke, David B. Miklos, Caron A. Jacobson, New England Journal of Medicine	2021	1.4K
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Journal of Clinical Oncology	2020	752
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study Stephen J. Schuster, Constantine S. Tam, Peter Borchmann, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMedicineLong-term Clinical OutcomesImmunology	2021	528
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial Nathan Fowler, Michael Dickinson, Martin Dreyling, Nature Medicine Lymphoid NeoplasiaHematologyImmunologyPathologyElara Trial	2021	492
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma Michael R. Bishop, Michael Dickinson, Duncan Purtill, New England Journal of Medicine	2021	491
Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease Partow Kebriaei, Luis Isola, Erkut Bahceci, Biology of Blood and Marrow Transplantation	2009	431
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten, New England Journal of Medicine	2023	359
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti–T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease–Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation Robert J. Soiffer, Haesook T. Kim, Joseph P. McGuirk, Journal of Clinical Oncology Cell TherapyGvhd ProphylaxisImmunologyImmunotherapyModerate-severe Cgvhd	2017	304
AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data Gary Calandra, John M. McCarty, Joseph P. McGuirk, Bone Marrow Transplantation Hematological MalignancyCell TherapyCompassionate Use DataMedicineImmunology	2007	277

Page 1